Help Get Patients to Their LDL-C and A1C Goals: Welchol® (colesevelam HCl) and the ADDvantage Program™
Patients taking medications for high cholesterol and diabetes have a new resource for managing their drug therapy.
This product bulletin was brought to you by Daiichi Sankyo, Inc.
This product bulletin describes the efficacy and safety of Welchol, a bile acid sequestrant. Welchol is the first and only add-on to a statin and metformin that is approved by the FDA as an adjunct to diet and exercise to lower both low-density lipoprotein cholesterol (LDL-C) and glycated hemoglobin (A1C) levels in adults with primary hyperlipidemia and type 2 diabetes mellitus. It also describes the ADDvantage Program, an innovative program to help keep patients on their LDL-C and A1C medications by enabling them to save money on multiple prescriptions and providing valuable resources and tools to help get them to their LDL-C and A1C goals.
To view the Welchol® (colesevelam HCl) product information, please click here.
To view the full product bulletin, please click here or the image below.
